The dyslipidemia in MASLD patients is considered to be the consequence of overproduction of hepatic apo B‐containing lipoproteins, primarily very‐low density lipoprotein (VLDL), which is remodeled to low‐density lipoprotein (LDL) in the circulation [2]. Here, APOB is linked to metabolic syndrome.